Wanbury Limited has informed the Exchange regarding Outcome of Board Meeting held on May 15, 2025.

Revenue Growth 20pctPat Growth 25pctExceptional ItemResults View source PDF Explain this filing

WANBURY · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

+9.0%Reaction day

₹279.18

prior close

₹323.00

announcement price

After-mkt

timing

Nifty Microcap 250market · in no size index; the smallest one is used+0.8%+8.3% vs market

Pharmaceuticals peers, median of 150sector+0.2%+8.9% vs sector

On the reaction day the stock moved 8.3 pts more than Nifty Microcap 250 and 8.9 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

+1.3

10m

-0.2

15m

-1.3

30m

-3.3

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

+9.0+0.8+8.3+0.2+8.9

Next day

+8.7+2.0+6.7+1.1+7.6

+3.6+0.9+2.7+0.1+3.5

+3.9+1.7+2.2+1.0+2.9

+3.5+1.6+2.0+1.2+2.4

+3.0+2.2+0.7+0.7+2.3

+2.4+2.7-0.3+1.2+1.3

15d

+6.3+4.5+1.8+0.6+5.7

+11.6+5.6+6.0+2.1+9.5

-3.6+9.0-12.6+4.1-7.8

-5.5+3.5-9.1-0.5-5.1

UpDownMarket · Nifty Microcap 250Sector · Pharmaceuticals peers, median of 150Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Wanbury Limited's Board approved audited standalone and consolidated results for Q4 and FY ending March 31, 2025, with an unmodified (clean) auditor opinion from Kapoor & Parekh Associates. Q4 FY25 revenue from operations jumped 23% year-on-year to about ₹17,200 lakhs, while Q4 profit after tax surged to ₹2,026 lakhs from ₹808 lakhs in Q4 FY24. Full-year FY25 revenue grew modestly to ₹59,951 lakhs (vs ₹57,774 lakhs) and full-year PAT was almost flat at ₹3,053 lakhs, as both manufacturing plants were shut for roughly 40 days during the year for scheduled upgrades. The company raised ₹17,500 lakhs via non-convertible debentures in Q4 to refinance high-cost debt and fund capex, and both USFDA (Patalganga) and ANVISA (Tanuku) inspections were cleared with zero adverse observations. Other equity swung positive to ₹2,650 lakhs from a negative ₹480 lakhs a year ago. Total borrowings stand at about ₹17,323 lakhs against equity of ₹5,927 lakhs, indicating leverage of roughly 2.9x.

Likely market impact

Near-term positive: strong Q4 rebound, clean audit, successful regulatory inspections, and balance sheet repair via NCD-led debt refinancing support sentiment. However, full-year earnings were essentially flat, leverage remains elevated near 3x, and operations are still recovering from the 40-day shutdown, so the stock may react with cautious optimism rather than a strong re-rating.